Compare Ascendis Pharma A/S (ASND) vs Newmont Corporation (NEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Newmont Corporation — how do they compare? Ascendis Pharma A/S trades at $253.39 (market cap $16.67B), while Newmont Corporation trades at $119.92 (market cap $123.50B). The key difference: Newmont Corporation is far larger — about 7.4× Ascendis Pharma A/S's market cap, and Newmont Corporation pays a 0.89% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NEM | |
|---|---|---|
Market Cap | $16.67B | $123.50B |
Sector | Health | Basic Materials |
52-Week High | $277.18 | $131.95 |
52-Week Low | $189.74 | $67.38 |
Enterprise Value | $17.04B | $120.09B |
Dividend Yield | — | 0.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Newmont Corporation (NEM) trades at $117.26, up 3.79% over 24 hours, near its 52-week high. The stock exhibits strong bullish technical signals and robust fundamentals, with revenue growing to $22.67 billion in 2025 and net income reaching $7.09 billion. Recent news highlights the resolution of a Nevada joint venture dispute with Barrick Mining, providing operational clarity.
The outlook for NEM remains positive, supported by strong earnings beats, a favorable analyst consensus, and rising gold prices. Key risks include gold price volatility and execution of production targets. The consensus price target of $133.00 suggests upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →
